Clinical utility of the pan-immune-inflammation value in intrahepatic cholangiocarcinoma patients

Abstract

Abstract Objectives The prognosis of pan-immune inflammatory value (PIV) in intrahepatic cholangiocarcinoma (ICCA) remains unclear. The aim of this study was to explore the clinical utility of the PIV in intrahepatic cholangiocarcinoma patients. Methods 138 patients with intrahepatic cholangiocarcinoma diagnosed for the first time were retrospectively collected. The optimal cutoff value for baseline PIV, determined by the maximally selected rank statistics method for OS. Based on the estimated cutoff value, 106 patients (75.5%) were included in the low PIV cohort (≤ 765.31) and 32 patients (24.5%) were included in the high PIV cohort (> 765.31). Results In the study, we showed that a novel pan-immune inflammatory value has an independent prognostic impact in patients with intrahepatic cholangiocarcinoma. Our results showed that high PIV is associated with a poorer OS prognosis. In addition, patients with high PIV and no surgery for the first time had a worse prognosis when stratified by baseline PIV and treatment regimen. Furthermore, early PIV variation and baseline as biomarkers to predict overall survival have added value, as its inclusion in the multivariate model also increased the concordance index. Conclusions In this study, we identified PIV as a novel biomarker that is strongly associated with the overall prognosis of patients with intrahepatic cholangiocarcinoma at first diagnosis. Of course, prospective validation of dynamic evaluation is still needed.